SR123781A: A New Once-Daily Synthetic Oligosaccharide Anticoagulant for Thromboprophylaxis After Total Hip Replacement Surgery. The DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) Study

Journal of the American College of Cardiology

Volumn 51, Issue 15, 2008, Pages 1498-1504

  Lassen, Michael R ^a   Dahl, Ola ^b   Mismetti, Patrick ^c   Zielske, Dirk ^d   Turpie, Alexander G G ^e  

^a Hoersholm Hospital   (Denmark)

^b THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^c UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; OLIGOSACCHARIDE; SR 123781A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PHLEBOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGOSACCHARIDES; PHLEBOGRAPHY; POLYSACCHARIDES; PROTHROMBIN; PULMONARY EMBOLISM; RISK FACTORS; SURGICAL PROCEDURES, ELECTIVE; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 41549156860     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.03.007     Document Type: Article

References (19)

1. Kurtz S., Ong K., Lau E., Mowat F., and Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 89 (2007) 780-785
2. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 338S-400S 126 Suppl
3. Salvati E.A., Pellegrini Jr. V.D., Sharrock N.E., et al. Recent advances in venous thromboembolic prophylaxis during and after total hip replacement. J Bone Joint Surg Am 82 (2000) 252-270
4. Fender D., Harper W.M., Thompson J.R., and Gregg P.J. Mortality and fatal pulmonary embolism after primary total hip replacement. Results from a regional hip register. J Bone Joint Surg Br 79 (1997) 896-899
5. Gillespie W., Murray D., Gregg P.J., and Warwick D. Risks and benefits of prophylaxis against venous thromboembolism in orthopaedic surgery. J Bone Joint Surg Br 82 (2000) 475-479
6. Warwick D., Williams M.H., and Bannister G.C. Death and thromboembolic disease after total hip replacement: a series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg Br 77 (1995) 6-10
7. Turpie A.G., Eriksson B.I., Lassen M.R., and Bauer K.A. Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol 10 (2003) 327-332
8. Ieko M. Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke. Curr Opin Investig Drugs 8 (2007) 758-768
9. Herbert J.M., Hérault J.P., Bernat A., et al. SR123781A, a synthetic heparin mimetic. Thromb Haemost 85 (2001) 852-860
10. Bal dit Sollier C., Kang C., Berge N., et al. Activity of a synthetic hexadecasaccharide (SanOrg123781A) in a pig model of arterial thrombosis. J Thromb Haemost 2 (2004) 925-930
11. Lorrain J., Lechaire I., Gauffeny C., et al. Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel. J Pharmacol Exp Ther 309 (2004) 235-240
12. Rabinov K., and Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 104 (1972) 134-144
13. Turpie A.G., Bauer K.A., Eriksson B.I., and Lassen M.R. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162 (2002) 1833-1840
14. Turpie A.G., Gallus A.S., Hoek J.A., and Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 344 (2001) 619-625
15. Eriksson B.I., Borris L.C., Dahl O.E., et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114 (2006) 2374-2381
16. Eriksson B.I., Borris L., Dahl O.E., et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4 (2006) 121-128
17. Eriksson B.I., Dahl O.E., Büller H.R., et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 3 (2005) 103-111
18. Lassen M.R., Bauer K.A., Eriksson B.I., Turpie A.G., and European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359 (2002) 1715-1720
19. Turpie A.G., Bauer K.A., Eriksson B.I., Lassen M.R., and PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359 (2002) 1721-1726